Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for CureVac N.V. (CVAC : NSDQ)
 
 • Company Description   
CureVac B.V. is a clinical-stage biopharmaceutical company. It engages in developing medicines based on messenger ribonucleic acid. The company's lead clinical programs include CV8102. CureVac B.V. is based in Germany.

Number of Employees: 455

 
 • Price / Volume Information   
Yesterday's Closing Price: $18.73 Daily Weekly Monthly
20 Day Moving Average: 590,825 shares
Shares Outstanding: 187.12 (millions)
Market Capitalization: $3,504.78 (millions)
Beta: 3.54
52 Week High: $125.66
52 Week Low: $14.20
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 10.96% 24.96%
12 Week 11.75% 22.85%
Year To Date -45.41% -30.88%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
Friedrich-Miescher-Strasse 15
-
Tubingen,2M 72076
DEU
ph: 49-70-71988-30
fax: 49-7071-9883
investors@curevac.com http://www.curevac.com
 
 • General Corporate Information   
Officers
Franz-Werner Haas - Chief Executive Officer
Baron Jean Stephenne - Chairman
Malte Greune - Chief Operating Officer
Pierre Kemula - Chief Financial Officer
Ralf Clemens - Director

Peer Information
CureVac N.V. (CORR.)
CureVac N.V. (RSPI)
CureVac N.V. (CGXP)
CureVac N.V. (BGEN)
CureVac N.V. (GTBP)
CureVac N.V. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: N2451R105
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: -
Next Expected EPS Date: 07/28/22
Share - Related Items
Shares Outstanding: 187.12
Most Recent Split Date: (:1)
Beta: 3.54
Market Capitalization: $3,504.78 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.86 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-2.61 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: 5.14% Last Dividend Paid: NA - $0.00
Next EPS Report Date: 07/28/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 4.54
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -
12/31/21 - -
09/30/21 - -
ROA
03/31/22 - -
12/31/21 - -
09/30/21 - -
Current Ratio
03/31/22 - -
12/31/21 - 2.63
09/30/21 - 1.79
Quick Ratio
03/31/22 - -
12/31/21 - 2.47
09/30/21 - 1.61
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -400.52
09/30/21 - -
Book Value
03/31/22 - -
12/31/21 - 4.13
09/30/21 - 4.39
Inventory Turnover
03/31/22 - -
12/31/21 - 2.33
09/30/21 - -
Debt-to-Equity
03/31/22 - -
12/31/21 - 0.04
09/30/21 - 0.04
Debt-to-Capital
03/31/22 - -
12/31/21 - 3.56
09/30/21 - 3.56
 

Powered by Zacks Investment Research ©